2025-02-17 - Analysis Report
## CRISPR Therapeutics AG (CRSP) Stock Report

**0. Executive Summary:**

CRISPR Therapeutics AG is a biopharmaceutical company focused on developing CRISPR/Cas9-based therapies.  The stock has significantly underperformed the S&P 500 (VOO) over various periods, showing high volatility and negative CAGR in recent years.  While recent price action shows a sharp increase, fundamental analysis reveals continued losses and concerns about long-term profitability.

**1. Performance Comparison:**

* **CRSP Cumulative Return:** 4.03%
* **VOO (S&P 500) Cumulative Return:** 116.18%
* **Return Difference:** -112.15%  (This indicates CRSP significantly underperformed VOO).
* **Relative Divergence:** 1.3 (This indicates CRSP's underperformance is in the lower 13th percentile of its historical range against VOO).

The provided Alpha and Beta analysis shows high volatility and inconsistent performance against the market (high Beta values) indicating high sensitivity to market fluctuations and questionable alpha generation.  Note that past performance is not indicative of future results.

**Alpha and Beta Analysis:**

| Year       | CAGR     | MDD     | Alpha | Beta | Cap(B) |
|------------|----------|---------|-------|-------|--------|
| 2016-2018  | -10.0%   | 24.5%   | -19.0% | 0.1   | 2.8    |
| 2017-2019  | 120.0%  | 24.5%   | 89.0%  | 0.8   | 6.0    |
| 2018-2020  | 269.0%  | 24.5%   | 241.0% | 0.3   | 15.0   |
| 2019-2021  | 72.0%   | 25.0%   | 1.0%   | 0.2   | 7.4    |
| 2020-2022  | -84.0%  | 25.1%   | -93.0% | 0.2   | 4.0    |
| 2021-2023  | -362.0% | 25.1%   | -386.0%| 2.2   | 6.1    |
| 2022-2024  | -79.0%  | 25.1%   | -111.0%| 2.5   | 3.9    |
| 2023-2025  | -26.0%  | 22.5%   | -89.0% | 3.4   | 4.3    |


**2. Recent Price Movement:**

* **Current Closing Price:** $43.49
* **Last Market Price:** $49.72 (a significant 14.33% increase from the previous close)
* **5-Day Moving Average:** $41.11
* **20-Day Moving Average:** $41.58
* **60-Day Moving Average:** $43.78

The recent price jump of 14.33% suggests a potential short-term bullish momentum. However, the price remains below all three moving averages, suggesting potential resistance.

**3. Technical Indicators:**

* **RSI:** 50.25 (Neutral; neither overbought nor oversold)
* **PPO:** 0.69 (Positive; suggesting a bullish momentum, albeit weak)
* **20-Day Relative Divergence Change:** +1.3 (Short-term upward trend)


The significant price increase (`Last-market`) indicates a sudden positive shift, potentially due to positive news or market sentiment not reflected in the provided data.  Given the magnitude of the price increase, this warrants further investigation into the causes for the price jump.

**Expected Return:** -711.7% This extremely negative expected return, compared to S&P 500, strongly suggests a highly risky investment, especially considering the company's financial status.


**4. Recent Earnings Analysis:**

| Date       | EPS     | Revenue    |
|------------|---------|------------|
| 2024-11-05 | -1.01   | $0.00 B    |
| 2024-08-05 | -1.49   | $0.00 B    |
| 2024-05-08 | -1.43   | $0.00 B    |
| 2023-11-06 | -1.41   | $0.00 B    |
| 2024-11-05 | -1.41   | $0.00 B    |


The company is consistently reporting negative EPS and zero revenue, indicating significant financial losses.  This is a major concern and needs to be addressed.  There appears to be a duplication of data for November 2024.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $0.04B  | 100.00%      |
| 2023-12-31 | $0.20B  | 90.00%       |

**Capital and Profitability:**

| Quarter | Equity  | ROE      |
|---------|---------|----------|
| 2024-12-31 | $1.93B  | -1.93%   |
| 2024-09-30 | $1.94B  | -4.43%   |
| 2024-06-30 | $1.98B  | -6.38%   |
| 2024-03-31 | $2.08B  | -5.59%   |
| 2023-12-31 | $1.88B  | 4.75%    |

While revenue increased slightly in Q4 2024, the company remains unprofitable. ROE is consistently negative, except for the last quarter of 2023, showing a worrying trend in profitability and return on investment. The extremely high profit margin for Q4 2024 needs clarification and further investigation.  The discrepancy between the reported revenue and the extremely high profit margin in Q4 2024 needs further investigation and clarification.


**6. Overall Analysis:**

CRISPR Therapeutics AG (CRSP) presents a highly risky investment.  While the recent price surge is noteworthy, it's crucial to remember that this doesn't negate the company's persistent losses and substantial underperformance against the market.  The high volatility, negative CAGR across multiple periods, and consistently negative EPS raise serious concerns.  A deeper dive into the reasons behind the recent price jump and a thorough analysis of the company's long-term prospects are crucial before making any investment decisions.  The extremely high profit margin in Q4 2024 needs clarification, and the financial data suggests a need for further due diligence. The negative expected return reinforces this high-risk assessment.  This report highlights the need for further research and due diligence before investing.
